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Protocol
AbstrACt
Introduction Granulocyte colony-stimulating factor 
(G-CSF) is generally used for neutropaenia. Previous 
experimental studies revealed that G-CSF promoted 
neurological recovery after spinal cord injury (SCI). Next, 
we moved to early phase of clinical trials. In a phase I/
IIa trial, no adverse events were observed. Next, we 
conducted a non-randomised, non-blinded, comparative 
trial, which suggested the efficacy of G-CSF for promoting 
neurological recovery. Based on those results, we are now 
performing a phase III trial.
Methods and analysis The objective of this study is to 
evaluate the efficacy of G-CSF for acute SCI. The study 
design is a prospective, multicentre, randomised, double-
blinded, placebo-controlled comparative study. The current 
trial includes cervical SCI (severity of American Spinal Injury 
Association (ASIA) Impairment Scale B/C) within 48 hours 
after injury. Patients are randomly assigned to G-CSF and 
placebo groups. The G-CSF group is administered 400 µg/
m2/day×5 days of G-CSF in normal saline via intravenous 
infusion for 5 consecutive days. The placebo group is 
similarly administered a placebo. Our primary endpoint is 
changes in ASIA motor scores from baseline to 3 months. 
Each group includes 44 patients (88 total patients).
Ethics and dissemination The study will be conducted 
according to the principles of the World Medical 
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Association Declaration of Helsinki and in accordance with the Japanese 
Medical Research Involving Human Subjects Act and other guidelines, 
regulations and Acts. Results of the clinical study will be submitted to the 
head of the respective clinical study site as a report after conclusion of 
the clinical study by the sponsor-investigator. Even if the results are not 
favourable despite conducting the clinical study properly, the data will be 
published as a paper.
trial registration number UMIN000018752.
IntroduCtIon
Spinal cord injury (SCI) is a devastating injury by which 
the patient can suffer from long-lasting severe sequelae 
including palsy of extremities, sensory disturbance, 
bowel/bladder/sexual dysfunction and neuropathic 
pain. Conceptually, SCI is divided into two chronolog-
ical phases: a primary and a secondary phase. Primary 
injury is mechanical damage to spinal cord tissue itself 
caused by fracture and/or dislocation or compression. 
Secondary injury is triggered by the primary injury and 
is a biological reaction of the spinal cord, which includes 
ischaemia, haemorrhage, excitotoxicity, hyperperme-
ability and inflammation.1 Because secondary injury can 
be the main target of treatment, extensive laboratory and 
clinical investigation of neuroprotection is needed to 
manage secondary injury.2 
To date, the only approved neuroprotective therapy 
for SCI is massive methylprednisolone sodium succinate 
(MPSS) therapy based on the NASCIS 2 study.3 However, 
recent reports revealed that MPSS shows only a modest 
effect for SCI. In addition, several reports have described 
adverse events induced by MPSS for SCI including infec-
tions (pneumonia, urinary tract infection) and gastro-
intestinal disorders (gastric ulcer, among others).4 
Therefore, the use of MPSS for SCI has become contro-
versial.5 Accordingly, a new therapeutic drug for SCI is 
desirable.
Granulocyte colony-stimulating factor (G-CSF, generic 
name: filgrastim) is a growth factor that affects the haema-
topoietic system, promoting differentiation, proliferation 
and survival of granulocytes.6 Clinically, in Japan, G-CSF is 
administered to patients with leucopenia, and to periph-
eral stem cell transplantation donors, G-CSF is admin-
istered to mobilise hematopoietic stem cells into the 
peripheral blood.7 In the central nervous system, G-CSF 
has properties to mobilise the movement of B cells into 
the brain8 and spine and, in a stroke model, has shown 
neuroprotective properties.9 In other countries, clinical 
studies of the effects of G-CSF in cerebral infarction have 
been reported.10
To prove the hypothesis that G-CSF has neuroprotec-
tive properties against SCI, G-CSF was administered to rat 
and mouse animal models of SCI, and hind limb func-
tion improved significantly after administration of G-CSF. 
Further investigations into the mechanism of action of 
G-CSF in SCI were conducted. Data obtained to date 
identify the following properties of G-CSF: (1) mobil-
isation of bone marrow-derived stem cells causing their 
biointegration at the site of SCI,11 (2) direct inhibition of 
nerve cell death,12 (3) protection of the myelin sheath by 
inhibiting oligodendrocyte cell death,13 (4) inhibition of 
inflammatory cytokine expression (TNF-α, IL-1β)13 and 
(5) promotion of neovascularisation.14 These properties 
suggest that G-CSF has a neuroprotective effect in acute 
SCI.
Based on these properties, a phase I/IIa clinical study 
was conducted where the main objective was to confirm 
the safety and feasibility of G-CSF for treatment of patients 
with acute SCI.15 This study was an open-label, dose-ti-
trating study with no control group. As the initial step, 5 
patients were given 5 µg/kg/day of G-CSF for 5 consec-
utive days by intravenous infusion, and as the second 
step, 11 patients were given 10 µg/kg/day of G-CSF for 
5 consecutive days by intravenous infusion. No serious 
adverse events were noted, and the safety of G-CSF admin-
istration in patients with acute SCI was confirmed.15
As a next step, to validate the efficacy of G-CSF in neuro-
protective treatment, a multicentre, prospective, non-ran-
domised, non-blinded, comparative control study (phase 
IIb clinical trial) was conducted.16 Based on the results 
of the previous phase I/IIa clinical trial, the dosage and 
duration of treatment with G-CSF in this study was 10 µg/
kg/day for 5 consecutive days. Patients with acute cervical 
SCI (within 48 hours of injury) were registered in the 
clinical trial and allocated to either the G-CSF group 
(G-CSF 10 µg/kg/day×5 days intravenous infusion) or 
control group (no G-CSF administration) at each treat-
ment facility. A total of 19 patients in the G-CSF group 
and 26 patients in the control group were observed for 
3 months or longer. American Spinal Injury Association 
(ASIA) motor score (motor: 0–100 points) was compared 
between the groups. ASIA motor scores were 26.1±18.9 
in the G-CSF group and 12.2±14.7 in the control group 
showing a significant improvement of motor paral-
ysis in the G-CSF group (p<0.01). In addition, in cases 
that could be followed for 1 year or longer, a significant 
improvement of ASIA motor score was observed in the 
G-CSF group.16
Based on results of these preclinical and early phase 
clinical trials, we are now conducting a phase III trial.
specific objective
The objective of this study is to evaluate the efficacy of 
G-CSF for improving motor paralysis in acute SCI.
strengths and limitations of this study
 ► Novel drug therapy for acute spinal cord injury (SCI) is much needed.
 ► Randomised, placebo-controlled, double-blinded design can elim-
inate bias.
 ► Patients with acute SCI are difficult to recruit to the trial.
 ► Patient’s neurological status in acute phase is unstable, possibly 
resulting in dispersion of the patient’s background.
 ► Concealment must be performed very strictly because granulocyte 
colony-stimulating factor apparently increases white blood cell 
count.
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MEthods And AnAlysIs
design of the study
The study design of the current trial is a prospective, 
multicentre, randomised, double-blinded, placebo-con-
trolled comparative study.
study procedures
The study outline is shown in figure 1. Patients will be 
randomly assigned to G-CSF and placebo groups. A central 
registration system will be used for dynamic randomisa-
tion into the investigational treatment group (G-CSF) and 
control group (placebo) based on age at registration (16–64 
years of age or 65–84 years of age) and severity of paralysis 
(AIS B or C) at 48 hours after injury. The surgical stabilisa-
tion and/or decompression was not included in stratifica-
tion. Initially, screened patients with severity AIS B/C will be 
tentatively enrolled. Initial screening of the patients include 
clinical laboratory test, imaging studies including X-ray, MRI 
and CT and neurological/functional evaluations.
Neurological reassessment will be performed 
48±4 hours after SCI and the patients who will recover to 
severity AIS D will be excluded. The patients with severity 
AIS B/C at neurological reassessment 48±4 hours after 
SCI will be enrolled and randomly allocated to either the 
investigational treatment group (G-CSF) or control group 
(placebo) in a 1-to-1 ratio. The subject registration centre 
uses a programme based on an appropriate computer 
algorithm to allocate patients into groups. The first dose 
of investigative drugs will be administered to the patients 
after reassessment of neurological status and enrolment 
48±4 hours after SCI.
Figure 1 Schematic diagram showing trial timeline. Cervical SCI with severity of AIS B/C within 48 hours after injury is 
recruited. Patients are randomly assigned to G-CSF and placebo groups. The G-CSF group is administered G-CSF in 
normal saline via intravenous infusion for 5 consecutive days. The placebo group is similarly administered a placebo. G-CSF, 
granulocyte colony-stimulating factor; SCI, spinal cord injury.  o
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The G-CSF group will be administered 400 µg/m2/
day×5 days of G-CSF in normal saline via intravenous 
infusion for 5 consecutive days. The placebo group will 
be similarly administered a placebo. The first dose of 
investigative drugs will be administered to the patients 
48±4 hours after SCI. The dosing schedule will be once a 
day in every morning (09:00–10:00 hours) for consecutive 
5 days even in case that the first dosing was performed at 
night because of restriction on practices. Investigational 
drugs including both G-CSF and placebo will be stored 
in refrigerator which will be kept between 1 and 6°C and 
have temperature-logger in pharmacies in each partici-
pating institutes. The investigational drugs are packaged 
in ample with label only printed as serial numbers, 10 
amples are packed in one box with label only printed 
serial numbers. Web-based allocation system will show the 
serial number of investigational drug which must be used 
to respective patients to ensure blinding.
We decided dosage of drug based on our previous 
non-randomised early phase clinical studies. On phase I/
IIa clinical study, of which study design was open-label, 
dose-titrating study with no control group, patients with 
SCI who were administered 10 µg/kg/day G-CSF for 5 
days showed marked elevation of white blood cell number 
(reached nearly 50 000/µL, of which white blood cell 
(WBC) number might cause adverse effects of G-CSF) 
during G-CSF administration.15 Therefore, we decided to 
withdraw additional titration. In addition, next phase of 
clinical study, of which design was multicentre, prospec-
tive, non-randomised, non-blinded, comparative control 
study, showed suggestive efficacy of G-CSF (10 µg/kg/
day for 5 days) for acute SCI.16 Based on those results, 
we finally decided the dosage of G-CSF as 10 µg/kg/
day×5 days for 5 days. In the current clinical trial, the 
dosage of G-CSF is written as 400 µg/m2/day (=10 µg/
kg/day) according to the Japanese Pharmaceutical and 
Medical Device Agency’s (PMDA) instruction for consoli-
dation with product labelling.
We decided to 48 hours after SCI as the therapeutic time 
window because our previous multicentre, prospective, 
non-randomised, non-blinded, comparative control study, 
which recruited patients with SCI within 48 hours after 
injury, showed that there was no significant difference in 
neurological outcome between the patient administered 
G-CSF very early after the injury and 48 hours after injury.16
Allocation will be concealed between blinded evalua-
tors of efficacy/safety and those for laboratory data, as 
G-CSF markedly increases white blood cell counts that 
can reveal patient treatment.
Our primary endpoint is changes in ASIA motor scores 
(international standards for neurological classification 
of spinal cord injury (ISNSCI),17 online supplementary 
figure 1) from baseline to 3 months calculated as follows: 
3 months ASIA motor score change=3 months ASIA motor 
score – pretreatment ASIA motor score. To maintain 
consistency of neurological assessment among the each 
evaluators, attending lecture and e-learning (in website of 
International Spinal Cord Society: http://www. elearnsci. 
org/) of ASIA/ISNSCI scoring system is mandatory for 
every investigators participating to the present trial.
Secondary endpoints are as follows. (1) Change in 
ASIA motor scores17 at 6 months and 12 months after 
G-CSF administration compared with pretreatment. (2) 
Changes in sensory paralysis over time: change in ASIA 
sensory scores at 3 months, 6 months and 12 months after 
G-CSF administration compared with pretreatment. (3) 
Severity of functional compromise because of paralysis: 
AIS before administration and at 3, 6 and 12 months after 
administration of G-CSF. (4) Percentage of responders: 
percentage of patients whose AIS improved by 1 grade or 
more at 3, 6 and 12 months after administration compared 
with before administration of G-CSF. (5) Neurological 
level of injury (NLI): percentage of patients whose NLI 
decreased by 1 grade of more at 3, 6 or 12 months after 
administration of G-CSF compared with pretreatment. 
(6) SCIM18: change in SCIM scores at 3, 6 and 12 months 
after G-CSF administration compared with pretreatment 
(7) EQ-5D19: measured EQ-5D efficacy scores at 3, 6 and 
12 months after G-CSF.
To strengthen the analysis, more strict blindness of 
assessment by the evaluator for outcome measures is 
ideal. Therefore, every prior score/measurement should 
be blinded and/or not the same person should assess 
every midpoint motor/sensory functional measurement. 
However, PMDA instructed us to assess one patients’ 
functional evaluation by one evaluator for consistent 
assessment in respective patients. PMDA considers the 
consistency of assessment in respective patients is more 
important.
The precise explanation of abovementioned outcome 
measures is as follows (online supplementary figures). 
ASIA motor score is determined by examining a function 
of 10 key muscles with manual muscle testing (MMT) 
in the supine position.17 The score ranges from 0 to 25 
for each extremity (MMT 0–5 in five muscles in each 
extremity), totalling 0–50 for the upper limbs and 0– 50 
for the lower limbs, resulting in total of ASIA motor score 
ranges from 0 to 100. ASIA motor score shows the degree 
of motor impairment induced by SCI (online supplemen-
tary figure 1).17 ASIA sensory scores are determined by 
sensory testing of a key point in each of the 28 dermatomes 
(from C2 to S4-5) on the each side of the body. Two 
aspects of sensation are examined, light touch and pin 
prick, at all the key points. Light touch and pin prick 
sensation are separately scored on a three-point scale: 
0=absent, 1=altered, 2=normal or intact. As a result, ASIA 
sensory scores range from 0 to 112 (online supplemen-
tary figure 1) in light touch and pin prick, respectively.17 
AIS is used for gross grading of impairment: A=Complete: 
No sensory or motor function is preserved in the sacral 
segments S4-S5. B=Sensory incomplete: Sensory but not 
motor function is preserved below the neurological level. 
C=Motor incomplete: Motor function is preserved below 
the neurological level, and more than half of key muscle 
functions below the single NLI have a muscle grade 
less than 3 (Grades 0–2). D=Motor incomplete: Motor 
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function is preserved below the neurological level, and at 
least half (half or more) of key muscle functions below the 
neurological level have a muscle grade >3. E = Normal:17 
If sensation and motor function as tested are graded as 
normal in all segments, and the patient had prior defi-
cits, then the AIS grade is E (online supplementary figure 
1, footnote).17 NLI refers to the most caudal segment 
of the cord with intact sensation and antigravity muscle 
function strength, provided that there is normal (intact) 
sensory and motor function rostrally (online supplemen-
tary figure 1, footnote).17 SCIM is disability scale devel-
oped specifically for patients with spinal cord lesions in 
order to make the functional assessments of patients with 
paraplegia or tetraplegia more sensitive to changes18. The 
SCIM includes the following areas of function: self-care 
(subscore (0–20), respiration and sphincter management 
(0–40) and mobility (0–40). Each area is scored according 
to its proportional weight in these patients’ general 
activity.18 The final score ranges from 0 to 100 (online 
supplementary figures 2–4). EQ-5D essentially consists 
of two pages19 (online supplementary figures 5 and 6): 
the EQ-5D descriptive system and the EQ visual analogue 
scale (EQ VAS). The descriptive system comprises five 
dimensions: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each dimension 
has five levels: no problems, slight problems, moderate 
problems, severe problems and extreme problems. The 
patient is asked to indicate his/her health state by ticking 
the box next to the most appropriate statement in each 
of the five dimensions.19 This decision results in a 1-digit 
number that expresses the level selected for that dimen-
sion. The digits for the five dimensions can be combined 
into a 5-digit number that describes the patient’s health 
state and can be converted to efficacy score with calibra-
tion scale (ranges −0.111 to 1.000).19 The EQ VAS records 
the patient’s self-rated health on a vertical visual analogue 
scale, where the endpoints are labelled ‘The best health 
you can imagine’ and ‘The worst health you can imagine’. 
The VAS can be used as a quantitative measure of health 
outcome that reflect the patient’s own judgement.19
Each group will include 44 patients (88 patients in 
total). Our protocol was approved by PMDA.
Inclusion
Inclusion criteria are as follows: (1) Patients with cervical 
SCI (severity of AIS B/C) within 48 hours of injury. (2) 
Patients reassessed for neurological status at 48 hours 
after injury, and those whose palsy is AIS B/C will be 
enrolled. (3) Patients with NLI between C4 and C7. (4) 
Patients with age of 16–85 years. (5) Patients who agree to 
participate in the current trial and from whom informed 
consent was obtained orally and in writing. (6) Patients 
who can be followed up for 12 months after SCI.
Exclusion
Exclusion criteria are as follows: (1) Patients with neuro-
logical recovery to AIS D at neurological reassessment 
48 hours after SCI, because only AIS B/C patients will be 
included to standardise the severity of paresis in order 
to stratify the patients at the initiation of drug admin-
istration. (2) Allergy to G-CSF. (3) Haematological 
malignancy, (4) within 6 months after invasive coronary 
intervention, (5) splenomegaly or (6) pregnancy, (7) 
consciousness impairment, (8) neurological disorders 
that can affect neurological evaluation in the present 
trial, (9) fracture of extremities that can affect the neuro-
logical evaluation and (10) massive dose administration 
of MPSS. Exclusion criteria 2–6 are set for safety, criteria 
1, 7–9 are set to maintain homogeneity of the patient 
population enrolled, criteria 7–9 are set for maintenance 
of accuracy of functional assessment, criterion 7 is set to 
obtain patients’ own informed consent on participation 
to the trial and criterion 10 is set to omit the possible 
interference of MPSS on outcome assessment.
Concealment
Patients will be administered drug or placebo and be eval-
uated in a double-blinded manner. An evaluator blinded 
to the treatment will take charge of patient evaluation 
including clinical findings and paresis, without laboratory 
data because G-CSF induces an apparent increase of white 
blood cell count that makes it easy to distinguish G-CSF and 
placebo treatment. Therefore, a non-blinded evaluator for 
laboratory data will be assigned to evaluate laboratory data 
alone. From a safety point of view, the dose of G-CSF will be 
modulated according to excessive increase of white blood 
cell count. Therefore, a non-blinded evaluator will instruct 
the pharmacy to modulate the dose of G-CSF based on white 
blood cell count.
sample size calculation
The target sample size for this randomised trial is 88. 
This number is based on the results of previous clinical 
trials.16 The estimated group difference (±SD) of change 
in ASIA motor scores from baseline to 3 months is 13.9 
(±21.9). A sample size of 44 patients in each group will 
provide 80% power to detect a difference of the change 
in ASIA motor scores between the G-CSF and the placebo 
treatments, using a mixed-effects models for repeated 
measures (MMRM) at a two-sided 5% level of signifi-
cance. A common correlation of 0.25 at each time point 
is assumed. A dropout rate of 10% is allowed. Thus, the 
total sample size of 88 patients is required for the trial.
statistical analyses
The analyses of the primary and secondary end points 
will be performed as intention-to-treat analyses in a full 
analysis set, which includes all patients who: (1) took at 
least one course of treatment during the study; (2) do not 
present any serious violation of the study protocol and 
(3) have data collected after commencement of treat-
ment. For the baseline characteristics, summary statistics 
will comprise frequencies and proportions for categorical 
variables and means and SDs for continuous variables. 
The patient characteristics will be compared using a χ² 
test for categorical variables and a t-test or Wilcoxon 
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rank-sum test for continuous variables. Missing data 
including loss to follow-up and missing measurement will 
be supplemented with MMRM.
For the primary analysis, aimed at comparing treat-
ment effects, a change in ASIA motor score from baseline 
to 3 months and its 95% CI will be estimated using the 
MMRM. To test for significant association of the primary 
endpoint, a MMRM with an unstructured covariance 
matrix will be applied to adjust for age (<65 years or ≥65 
years) and AIS at 48 hours after the injury (B or C).
For the secondary analysis, the change in ASIA motor 
score will be compared using a Student’s t-test and the 
95% CI will be estimated. The same method will be applied 
to change in sensory score, SCIM and EQ-5D. A χ² test will 
be applied to the frequencies of the responder in AIS and 
of the improvement in NLI. The frequency of American 
SPinal INjury Association Impairment Scale (AIS) will be 
summarised. The frequency of adverse events (AEs) will 
be compared using a Fisher’s exact test.
All comparisons are planned and all p values will be 
two sided. P<0.05 will be considered significant. All statis-
tical analyses will be performed using SAS software (V.9.4; 
SAS, Cary, North Carolina, USA). The statistical analysis 
plan will be developed by the principal investigator and 
the biostatistician before completion of patient recruit-
ment and fixing of data.
data monitoring committee
The data monitoring committee consists of three clinical 
trial specialists, including a biostatistician, who are inde-
pendent from the current study. The committee will meet 
at least two times per year and all the data obtained by the 
current trial will be checked by the committee.20
Adverse events
As for safety evaluation, adverse events will be collected as 
follows. ‘Adverse events’ refer to any untoward symptom 
or disease or signs of such (including clinical laboratory 
data abnormalities) in a clinical investigation subject after 
informed consent and does not necessarily have a causal 
relationship with the investigational product (G-CSF).
Increases in white blood counts will be considered 
an adverse event only when the count exceeds 50 000/
µL from the perspective of a pharmacological effect of 
G-CSF, and any values below this will not be handled as an 
adverse event. Anaphylaxis and adult respiratory distress 
syndrome are the most representative G-CSF-related 
severe adverse events to be paid full attention.
All adverse events will code terminology used by the 
investigators according to the ICH International Medical 
Dictionary for Regulatory Activities Japanese version 
(MedDRA/J).
EthICs And dIssEMInAtIon
Ethics
The study will be conducted according to the principles 
of the World Medical Association (WMA) Declaration 
of Helsinki—Ethical Principles for Medical Research 
Involving Human Subjects with the amendments made in 
Seoul, South Korea, October 2008, with a Note of Clar-
ification on Paragraph 29 added by the WMA General 
Assembly, Washington 2002; Note of Clarification on 
Paragraph 30 added by the WMA General Assembly, 
Tokyo 2004 and in accordance with the Japanese Medical 
Research Involving Human Subjects Act (WMO) and 
other guidelines, regulations and Acts.
Patient informed consent
The principal investigator will try to prepare the informed 
consent form and other explanatory materials in as simple 
language as possible in order to obtain informed consent 
from the patient and the patient’s legal representative. 
In case that trial participants cannot sign the informed 
consent form due to upper extremity palsy caused by SCI, 
allograph by patients’ representative will be allowed.
Public disclosure and publication policy
Results of the clinical study will be submitted to the head 
of the respective clinical study site as a report after conclu-
sion of the clinical study by the sponsor-investigator 
(includes study coordinating investigator). Even if the 
results are not favourable despite conducting the clinical 
study properly, the data will be published as a paper. Other 
sponsor-investigators (including the clinical study coordi-
nating investigator), if they plan to publicise the data from 
this study in a specialised academic society conference or 
other external site, must first obtain permission from the 
other principal investigators and investigational product 
provider. In publicising the results, the confidentiality of 
the subjects will be maintained and proofread in advance 
by the other sponsor-investigators (includes coordinating 
investigator) and investigational product provider.
dIsCussIon
The current trial is a confirmative trial to elucidate the 
therapeutic efficacy of G-CSF for SCI. If the current trial 
can successfully show significant improvement of motor 
paralysis of SCI by G-CSF, we will move forward to drug 
approval application to the Ministry for Health and 
Labor, Japan. The entire protocol of the current trial was 
approved beforehand for the initiation of the current 
trial by the Japanese PMDA. The PMDA will also permit a 
drug approval application if significant efficacy of G-CSF 
for SCI is proven.
The current trial is an important milestone for SCI 
clinics and research to explore G-CSF for SCI.
trial status
The present trial is now ongoing.
trial sites
Nineteen major hospitals in Japan constituting the 
G-SPIRIT study group are as follows: Tohoku Univer-
sity Hospital, Miyagi; Niigata University, Niigata; Dokkyo 
University Hospital, Tochigi; Tsukuba University Hospital, 
Ibaraki; Tsukuba Medical Center, Ibaraki; Chiba University 
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Hospital, Chiba; Funabashi Municipal Medical Center, 
Chiba; Kimitsu Chuo Hospital, Chiba; Chiba Rosai 
Hospital, Chiba; Tokai University Hospital, Kanagawa; 
Hamamatsu University Hospital, Shizuoka; Gifu University 
Hospital, Gifu; Chubu Rosai Hospital, Aichi; Mie University 
Hospital, Mie; Kanazawa Medical Collage, Ishikawa; Kobe 
Red Cross Hospital, Hyogo; Hiroshima University Hospital, 
Hiroshima; Yamaguchi University Hospital, Yamaguchi and 
Nagasaki Rosai Hospital, Nagasaki.
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